Indeed, this antagonism may largely explain the tumor suppressor function of Ikaros in BCP-ALL, where IKZF1 loss-of-function mutations are most prevalent in subtypes exhibiting activated JAK/STAT5 signaling. The gene discussed is IKZF1; the disease is neoplasm.